The development and use of cutting-edge genomic technologies to probe and control the human immune system is at the center of the groundbreaking research at the Gladstone-UCSF Institute of Genomic Immunology. Researchers combine advanced genomic profiling and functional screening with spatial mapping of human tumors to define the genetic programs that can be manipulated to enhance immune cell therapies. Working with the PICI network, Gladstone investigators are generating comprehensive atlases of cancer immunity and designing next-generation immunotherapies for clinical testing. PICI at Gladstone Institutes is harnessing the power of genomics and CRISPR technologies to program the human immune system to treat cancer. Areas of scientific interest: Multimodal genomic profiling of patient immune cells Spatial mapping of the tumor immune compartment Systematic functional genetic screening in human immune cells Synthetic programming of cellular immunotherapies Alexander Marson, MD, PhD | Director All Investigators Related Announcement, Our Impact, Research Update New CAR-T Approach Shows Promise for Lymphoma Patients Announcement PICI Young Investigator Retreat 2019 Research Update Colorectal cancer genetics study sheds light on why some patients are resistant to treatment Announcement, Our Impact PICI at AACR 2025: Data, Direction, Impact Announcement, Press Release Dr. Ira Mellman Joins PICI as President of Research Announcement, Press Release Dr. Karen E. Knudsen Appointed CEO of PICI From Bench to Fireside From Metastatic Melanoma to Immune Engineering with Antoni Ribas, MD, PhD Announcement, From Bench to Fireside Dr. Elizabeth Mittendorf on breast cancer breakthroughs Announcement, From Bench to Fireside PICI’s From Bench to Fireside Podcast Returns
Research Update Colorectal cancer genetics study sheds light on why some patients are resistant to treatment